Based on CKD patients’ individual treatment goals, classical LDL lipid-lowering therapeutic strategies are based on oral medication, including statins, ezetimibe, and bempedoic acid, or the subcutaneous application of PCSK9 inhibitors [2,54,55]. Here, PCSK9 is linked to chronic kidney disease.